Home Cart Sign in  
Chemical Structure| 1092939-17-7 Chemical Structure| 1092939-17-7

Structure of Ruxolitinib phosphate
CAS No.: 1092939-17-7

Chemical Structure| 1092939-17-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ruxolitinib phosphate (INCB018424 phosphate) is a powerful JAK1/2 inhibitor with IC50 values of 3.3 nM and 2.8 nM, respectively, demonstrating more than 130-fold selectivity over JAK3.

Synonyms: INCB018424 phosphate; Ruxolitinib (phosphate); INCB 018424 (phosphate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ruxolitinib phosphate

CAS No. :1092939-17-7
Formula : C17H21N6O4P
M.W : 404.36
SMILES Code : N#CC[C@@H](N1N=CC(C2=C3C(NC=C3)=NC=N2)=C1)C4CCCC4.O=P(O)(O)O
Synonyms :
INCB018424 phosphate; Ruxolitinib (phosphate); INCB 018424 (phosphate)
MDL No. :MFCD18452860
InChI Key :JFMWPOCYMYGEDM-XFULWGLBSA-N
Pubchem ID :25127112

Safety of Ruxolitinib phosphate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P280-P305+P351+P338-P310

Related Pathways of Ruxolitinib phosphate

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BA/F3 JAK2 V617F cells 35 nM 48-72 h To evaluate the inhibitory effect of Ruxolitinib on JAK2 V617F mutant cells, results showed that Ruxolitinib effectively inhibited the viability of BA/F3 JAK2 V617F cells PMC6518898
SET2 cells 25 nM 48-72 h To evaluate the inhibitory effect of Ruxolitinib on JAK2 V617F mutant cells, results showed that Ruxolitinib effectively inhibited the viability of SET2 cells PMC6518898
HS27a cells 100 nM 1 h To evaluate the effect of Ruxolitinib on collagen expression in HS27a cells, results showed that Ruxolitinib in combination with Nilotinib and Prednisone significantly inhibited collagen expression PMC6518898
LX-2 cells 0.1–100 μM Ruxolitinib inhibits cell proliferation in a dose and time-dependent manner in LX-2 cells, with an IC50 value of 14.01 μM. PMC8981941
HDLM-2 cells 10-100 nM 24 h significantly inhibited downstream active phosphorylated STAT3 and STAT5 PMC5839401
L-428 cells 25 nM 48 h significantly downregulated phosphorylation of STAT3, STAT5 and STAT6 PMC5839401
Karpas-1106P cells 25 nM 48 h significant inhibition of phosphorylation of STAT3 and STAT6 PMC5839401
L-428 cells 1, 10, 100 uM 48 h significant decrease in cell proliferation PMC5839401
HDLM-2 cells 1, 10, 100 uM 48 h significant inhibition of cell proliferation PMC5839401
Karpas-1106P cells 1, 10, 100 uM 48 h significant inhibition of cell proliferation PMC5839401
NRK-49F cells 5μM 24 h Suppressed TGF-β1-induced NRK-49F cell proliferation and down-regulated TGF-β1-induced α-SMA expression PMC6949153
NRK-52E cells 5μM 24 h Suppressed TGF-β1-induced NRK-52E cell EMT PMC6949153
ETP-ALL PDX cells 1 μM 1 h Inhibition of JAK/STAT signaling, validating the sensitivity of ETP-ALL cells to Ruxolitinib PMC8670248
mT3–2D cells 1 μg/mL 12 h inhibited the expression of CCL9 and ARG1 PMC8283778
other KPC cell lines 1 μg/mL 12 h inhibited the expression of CCL9 and ARG1 PMC8283778
UKE-1 cells 300 nM 72 h To evaluate the pharmacodynamic effects of the triple combination of Ruxolitinib, PIM447, and LEE011 on UKE-1 cells, the results showed that the triple combination significantly reduced pSTAT5, pBAD, and pRB levels and increased apoptosis. PMC8197756

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CCl4-induced liver fibrosis model Oral gavage 30 mg/kg Once daily for 4 weeks Ruxolitinib significantly attenuated CCl4-induced liver fibrosis, inhibited the activation of HSCs, and partially protected the liver from damage. PMC8981941
NSG mice HL and PMBL xenograft model oral 45.0 mg/kg for 21 days significantly prolonged survival and decreased tumor burden PMC5839401
C57BL/6 mice Unilateral ureteral obstruction (UUO) model Oral 30 mg/kg Twice daily for 14 days Ameliorated UUO-induced renal interstitial fibrosis, and inhibited Stat3 and Akt/mTOR/Yap pathways PMC6949153
C57BL/6J mice mT3–2D tumor model oral 50 mg/kg daily for 4 weeks improved the anti-tumor efficacy of anti-PD-1 treatment PMC8283778
Mice UKE-1 leukemia xenograft model Oral gavage 60mg/kg Twice daily, continuous treatment To evaluate the therapeutic efficacy of the triple combination of Ruxolitinib, PIM447, and LEE011 in the UKE-1 leukemia xenograft model, the results showed that the triple combination significantly inhibited tumor growth and prolonged survival in mice. PMC8197756

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03616184 Graft-versus-host-disease (GVH... More >>D) Less << Phase 2 Recruiting April 2024 United States, Nebraska ... More >> University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Penny Nurse Coordinator, RN    402-559-4596 Less <<
NCT03386214 Myelofibroses Phase 1 Recruiting March 31, 2021 United States, Missouri ... More >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh, M.D., Ph.D.    314-747-7960    stoh@wustl.edu    Principal Investigator: Stephen Oh, M.D., Ph.D.          Sub-Investigator: Amy Zhou, M.D. Less <<
NCT00674479 Acute Myeloid Leukemia ... More >> Acute Lymphocytic Leukemia Myelodysplastic Syndrome Chronic Myelogenous Leukemia Less << Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02119650 - Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT02119650 NSCLC (Non-small Cell Lung Car... More >>cinoma) Less << Phase 2 Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT01730755 - - - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT02475655 HIV Infections Phase 2 Completed - United States, Alabama ... More >> Alabama CRS Birmingham, Alabama, United States, 35294 United States, California UCLA CARE Center CRS Los Angeles, California, United States, 90035 UCSD Antiviral Research Center CRS San Diego, California, United States, 92103 Ucsf Hiv/Aids Crs San Francisco, California, United States, 94110 United States, Illinois Northwestern University CRS Chicago, Illinois, United States, 60611 United States, Missouri Washington University Therapeutics (WT) CRS Saint Louis, Missouri, United States, 63110-1010 United States, New York Weill Cornell Chelsea CRS New York, New York, United States, 10010 Weill Cornell Uptown CRS New York, New York, United States, 10065 University of Rochester Adult HIV Therapeutic Strategies Network CRS Rochester, New York, United States, 14642 United States, Ohio Cincinnati Clinical Research Site Cincinnati, Ohio, United States, 45219 Case Clinical Research Site Cleveland, Ohio, United States, 44106 United States, Pennsylvania Penn Therapeutics, CRS Philadelphia, Pennsylvania, United States, 19104 United States, Rhode Island The Miriam Hospital Clinical Research Site (TMH CRS) CRS Providence, Rhode Island, United States, 02906 United States, Tennessee Vanderbilt Therapeutics (VT) CRS Nashville, Tennessee, United States, 37204 Less <<
NCT02420717 Leukemia Phase 2 Recruiting July 2023 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT02997280 Graft Vs Host Disease Phase 2 Recruiting June 2019 Russian Federation ... More >> First Pavlov State Medical University of St. Petersburg Recruiting Saint-Petersburg, Russian Federation, 197089 Contact: Ivan S. Moiseev, PhD    +79217961951    moisiv@mail.ru    Contact: Boris V. Afanasyev, Prof    +78122334551    coordinatorbmt@gmail.com Less <<
NCT02553330 Alopecia Areata (AA) Phase 2 Terminated(The study was termi... More >>nated early based on the results of a planned interim analysis.) Less << - United States, Alabama ... More >> Birmingham, Alabama, United States United States, Arkansas Hot Springs, Arkansas, United States United States, Connecticut New Haven, Connecticut, United States Trumbull, Connecticut, United States United States, Florida Miami, Florida, United States United States, Massachusetts Beverly, Massachusetts, United States Boston, Massachusetts, United States United States, Michigan Clinton Township, Michigan, United States Fort Gratiot, Michigan, United States United States, Minnesota Fridley, Minnesota, United States Minneapolis, Minnesota, United States United States, North Carolina Winston-Salem, North Carolina, United States United States, Ohio Cleveland, Ohio, United States United States, Oregon Portland, Oregon, United States United States, Texas Austin, Texas, United States Houston, Texas, United States Katy, Texas, United States United States, Virginia Norfolk, Virginia, United States Less <<
NCT01317875 Myelofibrosis Phase 1 Active, not recruiting September 2020 United States, Florida ... More >> Winter Park, Florida, United States, 32789 United States, Maryland Baltimore, Maryland, United States, 21229 United States, Texas Houston, Texas, United States, 77030 Austria Vienna, Austria China, Jiangsu Nanjing, Jiangsu, China China, Sichuan Chengdu, Sichuan, China China, Zhejiang Hangzhou, Zhejiang, China China Beijing, China France Angers, France Paris, France Pierre-Benite, France Germany Leipzig, Germany Italy Firenze, Italy Milano, Italy Terni, Italy Netherlands Rotterdam, Netherlands United Kingdom Belfast, United Kingdom London, United Kingdom Less <<
NCT02292446 Polycythemia Vera Phase 3 Completed - -
NCT03373877 Myelofibrosis ... More >> Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << Phase 1 Recruiting December 2019 United States, Connecticut ... More >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06511 Contact: Kris Awerkamp, BSN RN CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Nikolai Podoltsev, MD PhD          United States, Louisiana Ochsner Clinic Foundation Recruiting New Orleans, Louisiana, United States, 70121 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Laura Finn, MD          United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Moshe Talpaz, MD          Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Jay Yang, MD          United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Krishna Gundabolu, MD          United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Kris Awerkamp, BSN RN CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Murat Arcasoy, MD          United States, Ohio Cleveland Clinic - Taussig Cancer Institute Recruiting Cleveland, Ohio, United States, 44195 Contact: Kris Awerkamp, BSN RN CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Moshe Talpaz, MD          United States, Pennsylvania Abramson Cancer Center - University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Elizabeth Hexner, MD          United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Kris Awerkamp, BSN, RN    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Naveen Pemmaraju, MD          Mays Cancer Center UT Health San Antonio Recruiting San Antonio, Texas, United States, 78229-3900 Contact: Kris Awerkamp, BSN, RN, CCRP    602-358-8319    kawerkamp@td2inc.com    Principal Investigator: Ruben A. Mesa, MD, FACP Less <<
NCT00820950 Psoriasis Phase 2 Completed - United States, California ... More >> Vallejo, California, United States United States, Massachusetts Boston, Massachusetts, United States United States, New York Rochester, New York, United States Stony Brook, New York, United States United States, Oregon Portland, Oregon, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States Less <<
NCT02119663 Pancreatic Cancer Phase 3 Terminated(The safety committe... More >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) Less << - -
NCT02038036 Polycythemia Vera Phase 3 Active, not recruiting April 8, 2020 -
NCT02117479 Pancreatic Cancer Phase 3 Terminated(The study was termi... More >>nated early based on the results of the planned interim analysis.) Less << - -
NCT02713386 Fallopian Tube Clear Cell Aden... More >>ocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Serous Neoplasm High Grade Ovarian Serous Adenocarcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Stage III Fallopian Tube Cancer AJCC v7 Stage III Ovarian Cancer AJCC v6 and v7 Stage III Primary Peritoneal Cancer AJCC v7 Stage IIIA Fallopian Tube Cancer AJCC v7 Stage IIIA Ovarian Cancer AJCC v6 and v7 Stage IIIA Primary Peritoneal Cancer AJCC v7 Stage IIIB Fallopian Tube Cancer AJCC v7 Stage IIIB Ovarian Cancer AJCC v6 and v7 Stage IIIB Primary Peritoneal Cancer AJCC v7 Stage IIIC Fallopian Tube Cancer AJCC v7 Stage IIIC Ovarian Cancer AJCC v6 and v7 Stage IIIC Primary Peritoneal Cancer AJCC v7 Stage IV Fallopian Tube Cancer AJCC v6 and v7 Stage IV Ovarian Cancer AJCC v6 and v7 Stage IV Primary Peritoneal Cancer AJCC v7 Less << Phase 1 Phase 2 Recruiting - United States, Illinois ... More >> University of Chicago Comprehensive Cancer Center Recruiting Chicago, Illinois, United States, 60637 Contact: John W. Moroney    773-834-7424       Principal Investigator: John W. Moroney          United States, Iowa University of Iowa/Holden Comprehensive Cancer Center Recruiting Iowa City, Iowa, United States, 52242 Contact: David P. Bender    800-237-1225       Principal Investigator: David P. Bender          United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Deborah K. Armstrong    410-955-8804    jhcccro@jhmi.edu    Principal Investigator: Deborah K. Armstrong          United States, Ohio Cleveland Clinic Foundation Recruiting Cleveland, Ohio, United States, 44195 Contact: Peter G. Rose    866-223-8100       Principal Investigator: Peter G. Rose          United States, Oklahoma University of Oklahoma Health Sciences Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Robert S. Mannel    405-271-8777    ou-clinical-trials@ouhsc.edu    Principal Investigator: Robert S. Mannel          United States, Pennsylvania NRG Oncology Recruiting Philadelphia, Pennsylvania, United States, 19103 Contact: Robert A. Burger    215-573-5129    robert.burger@uphs.upenn.edu    Principal Investigator: Robert A. Burger          University of Pennsylvania/Abramson Cancer Center Suspended Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Alexander B. Olawaiye    412-647-8073       Principal Investigator: Alexander B. Olawaiye          United States, Rhode Island Women and Infants Hospital Recruiting Providence, Rhode Island, United States, 02905 Contact: Cara A. Mathews    401-274-1122       Principal Investigator: Cara A. Mathews          United States, Virginia University of Virginia Cancer Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: Charles N. Landen    434-243-6322    JME3D@hscmail.mcc.virginia.edu    Principal Investigator: Charles N. Landen          United States, Wisconsin Froedtert and the Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: William H. Bradley    414-805-4380       Principal Investigator: William H. Bradley Less <<
NCT02117479 - Terminated(The study was termi... More >>nated early based on the results of the planned interim analysis.) Less << - -
NCT01375140 Myeloproliferative Diseases Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02396628 Graft vs Host Disease Phase 2 Recruiting March 2023 Germany ... More >> Charité - Universitätsmedizin Berlin Recruiting Berlin, Germany, 13353 Principal Investigator: Igor Blau, PD Dr.          Sub-Investigator: Il-Kang Na, PD Dr.          Sub-Investigator: Giang Lam Vuong, Dr.          Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Principal Investigator: Dominik Wolf, Prof.          Sub-Investigator: Karin Mayer, Dr.          Universitätsklinikum Dresden Recruiting Dresden, Germany, 01307 Principal Investigator: Friedrich Stölzel, Dr.          Sub-Investigator: Rainer Ordemann, Prof.          University Medical Center Recruiting Freiburg, Germany, 79106 Contact: Nikolas von Bubnoff, Professor       nikolas.bubnoff@uniklinik-freiburg.de    Principal Investigator: Nikolas von Bubnoff, Professor          Sub-Investigator: Robert Zeiser, Professor          Universitätsklinikum Hamburg Eppendorf Recruiting Hamburg, Germany, 20246 Principal Investigator: Francis Ayuk, PD Dr.          Sub-Investigator: Dietlinde Janson, Dr.          Universitätsklinikum Heidelberg Recruiting Heidelberg, Germany, 69120 Principal Investigator: Peter Dreger, Prof.          Sub-Investigator: Thomas Luft, PD Dr.          Universitätsklinikum des Saarlandes Recruiting Homburg, Germany, 66421 Contact: Jörg T. Bittenbring, Dr.          Principal Investigator: Jörg T. Bittenbring, Dr.          Sub-Investigator: Niels Murawski, PD Dr.          Universitätsklinikum Köln Recruiting Köln, Germany, 50937 Contact: Udo Holtick, Dr.          Principal Investigator: Udo Holtick, Dr.          Sub-Investigator: Christof Scheid, Prof.          Sub-Investigator: Marco Herling, Dr.          Universitätsklinikum Marburg Recruiting Marburg, Germany, 35043 Contact: Andreas Burchert, Prof.          Principal Investigator: Andreas Burchert, Prof.          Sub-Investigator: Kristina Sohlbach, Dr.          Universitätsklinikum München TU rechts der Isar Recruiting München, Germany, 81675 Principal Investigator: Mareike Verbeek, Dr.          Sub-Investigator: Sandra Grass, Dr.          Universitätsklinikum Würzburg Recruiting Würzburg, Germany, 97080 Principal Investigator: Götz Grigoleit, Dr.          Sub-Investigator: Sabrina Kraus, Dr. Less <<
NCT02119663 - Terminated(The safety committe... More >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) Less << - -
NCT02598297 Early Myelofibrosis With High ... More >>Molecular Risk Mutations Less << Phase 3 Completed - -
NCT02119676 - Terminated(Substudy 1 was term... More >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) Less << - -
NCT02966353 Primary Myelofibrosis ... More >> Post-Polycythemia Vera-Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Less << Phase 2 Active, not recruiting February 15, 2019 Austria ... More >> Novartis Investigative Site Vienna, Austria, A-1090 Belgium Novartis Investigative Site Antwerpen, Belgium, 2060 Novartis Investigative Site Leuven, Belgium, 3000 Bulgaria Novartis Investigative Site Sofia, Bulgaria, 1413 Novartis Investigative Site Sofia, Bulgaria, 1756 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1M9 Germany Novartis Investigative Site Halle/S., Germany, 06120 Greece Novartis Investigative Site Thessaloniki, GR, Greece, 570 10 Novartis Investigative Site Athens, Greece, 11527 Italy Novartis Investigative Site Bologna, BO, Italy, 40138 Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Palermo, PA, Italy, 90127 Japan Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8431 Russian Federation Novartis Investigative Site Moscow, Russian Federation, 125167 Novartis Investigative Site Moscow, Russian Federation, 129110 Novartis Investigative Site Petrozavodsk, Russian Federation, 185019 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Alicante, Comunidad Valenciana, Spain, 03010 Novartis Investigative Site Santiago de Compostela, Galicia, Spain, 15706 Turkey Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Kocaeli, Turkey, 41380 Less <<
NCT02436135 Myelofibrosis Phase 1 Completed - United States, California ... More >> Stanford Hospital and Clinics Stanford, California, United States, 94305 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Less <<
NCT03697460 Lichen Planus Phase 2 Recruiting July 2020 United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Narcelle Jean-Louis    480-301-4714    JeanLouis.Narcelle@mayo.edu    Principal Investigator: Aaron R Mangold Less <<
NCT03144687 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 2 Recruiting March 2019 United States, Arizona ... More >> Arizona Oncology Associates Recruiting Tempe, Arizona, United States, 85284 Contact: Study Coordinator    480-256-1664       Principal Investigator: Kasra Karamlou          United States, California UC Irvine Medical Center Recruiting Orange, California, United States, 92868 Contact: Study Coordinator    714-456-5408       Principal Investigator: Angela Fleischman, MD          United States, Colorado Anschutz Cancer Pavilion - University Of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Study Coordinator    720-848-2587       Principal Investigator: Brandon McMahon          United States, Connecticut Norwalk Hospital Recruiting Norwalk, Connecticut, United States, 06856 Contact: Study Coordinator    203-852-2996       Principal Investigator: Richard Frank          United States, District of Columbia Georgetown University Hospital Not yet recruiting Washington, District of Columbia, United States, 20007 Contact: Study Coordinator    202-687-0116       Principal Investigator: Craig Kessler          United States, Indiana Parkview Research Center Recruiting Fort Wayne, Indiana, United States, 46845 Contact: Study Coordinator    260-425-6831       Principal Investigator: Robert Manges          United States, Maryland University Of Maryland - Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Study Coordinator    410-328-6635       Principal Investigator: Duong          United States, Michigan University of Michigan Health System Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Study Coordinator    734-936-3879       Principal Investigator: Moshe Talpaz, MD          Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Study Coordinator    313-576-9758       Principal Investigator: Jay Yang          Providence Cancer Center Recruiting Southfield, Michigan, United States, 48075 Contact: Study Coordinator    248-849-5332       Principal Investigator: Howard Terebelo          United States, New Mexico University Of New Mexico Cancer Center Recruiting Albuquerque, New Mexico, United States, 87102 Contact: Study Coordinator    505-925-0379       Principal Investigator: Arana Yi          United States, New York Weill Cornell Medical Centers Not yet recruiting New York, New York, United States, 10065 Contact: Study Coordinator    212-746-2389       Principal Investigator: Ellen Ritchie          New York Medical College Not yet recruiting Valhalla, New York, United States, 10595 Contact: Study Coordinator    914-493-8375       Principal Investigator: Karen Seiter          United States, North Carolina Duke University Medical Center Not yet recruiting Durham, North Carolina, United States, 27710 Contact: Study Coordinator    919-681-4769       Principal Investigator: Murat Arcasoy          United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Study Coordinator    216-444-9464       Principal Investigator: Aaron Gerds, MD          United States, Oregon Willamette Valley Cancer Institute Recruiting Eugene, Oregon, United States, 97401 Contact: Study Coordinator    281-863-4631       Principal Investigator: Jeff Sharman, MD          United States, Texas Texas Oncology San Antonio Recruiting San Antonio, Texas, United States, 78240 Contact: Study Coordinator    210-595-5680       Principal Investigator: Roger Lyons          Texas Oncology - Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Study Coordinator    903-579-9800       Principal Investigator: Habte Yimer          United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Study Coordinator    434-982-3927       Principal Investigator: Michael Keng, MD Less <<
NCT02119676 CRC (Colorectal Cancer) Phase 2 Terminated(Substudy 1 was term... More >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) Less << - -
NCT03011892 Atopic Dermatitis Phase 2 Completed - -
NCT01644110 Primary Myelofibrosis ... More >> Secondary Myelofibrosis PMF SMF Post-PV MF Post-ET MF Less << Phase 1 Phase 2 Recruiting May 2022 Germany ... More >> University of Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Doehner, MD       konstanze.doehner@uniklinik-ulm.de    Principal Investigator: konstanze Doehner, Md Less <<
NCT02120417 Breast Cancer Phase 2 Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT02253277 Chronic Myeloid Leukemia Phase 1 Phase 2 Completed - Germany ... More >> Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Jena, Germany, 07740 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Mannheim, Germany, 68169 Less <<
NCT02955940 Pancreatic Cancer ... More >> Colorectal Cancer (CRC) Breast Cancer Lung Cancer Less << Phase 2 Enrolling by invitation November 2019 United States, Kentucky ... More >> University of Louisville Louisville, Kentucky, United States, 40202 United States, New York New York Oncology Hematology PC Hudson, New York, United States, 12534 United States, Texas U of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02120417 - Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << - -
NCT02076191 Myeloproliferative Neoplasms Phase 1 Phase 2 Active, not recruiting December 2018 United States, Missouri ... More >> Washington University of St. Louis Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Columbia University Medical Center New York, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Wake Forest University Baptist Medical Center Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Taussig Cancer Center Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT02400463 Hemophagocytic Syndrome (HPS) Early Phase 1 Recruiting November 2018 United States, Michigan ... More >> University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Ryan Wilcox, M.D.    734-615-1482    rywilcox@umich.edu    Principal Investigator: Ryan Wilcox, M.D. Less <<
NCT03701698 Acute GVHD Phase 2 Not yet recruiting October 31, 2021 China, Shanghai ... More >> Shanghai General Hospital Active, not recruiting Shanghai, Shanghai, China, 200080 Less <<
NCT02091752 Primary Myelofibrosis Phase 2 Terminated(The study was termi... More >>nated due to low enrollment.) Less << - Germany ... More >> Novartis Investigative Site Leipzig, Germany, 04103 Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Spain Novartis Investigative Site Madrid, Spain, 28034 Less <<
NCT01348490 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 2 Active, not recruiting November 2018 -
NCT03274778 Prostate Cancer Not Applicable Recruiting May 1, 2019 Switzerland ... More >> Istituto Oncologico della Svizzera Italiana (IOSI) Recruiting Bellinzona, Switzerland, 6500 Contact: Ricardo Pereira Mestre, Dr. med.    +41 (0)91 811 84 46    Ricardo.PereiraMestre@eoc.ch    Contact: Barbara Marongiu    +41 (0)91 811 91 20    barbara.marongiu@eoc.ch Less <<
NCT03069326 Myelofibrosis Phase 2 Recruiting February 2019 United States, New Jersey ... More >> Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Raajit Rampal, MD, PhD    212-639-2194       United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Raajit Rampa, MD, PhD    212-639-2194       Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Raajit Rampal, MD, PhD    212-639-2194       Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Raajit Rampal, MD, PhD    212-639-2194       Contact: Ellin Berman, MD    212-639-7762       Principal Investigator: Raajit Rampal, MD, PhD          Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Raajit Rampal, MD, PhD    212-639-2194       United States, Texas Md Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Prithvira Bose, MD    713-792-7747       Principal Investigator: Prithvira Bose, MD Less <<
NCT02091752 - Terminated(The study was termi... More >>nated due to low enrollment.) Less << - -
NCT01776723 Myelomonocytic Leukemia Phase 1 Phase 2 Active, not recruiting April 2020 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Maryland Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Weill Medical College of Cornell New York, New York, United States, 10021 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44106 Less <<
NCT00952289 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 3 Completed - -
NCT02876302 Inflammatory Breast Cancer (IB... More >>C) Less << Phase 2 Recruiting February 2024 United States, Maryland ... More >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Vered Stearns, MD       vstearn1@jhmi.edu    Johns Hopkins at Green Spring Station Recruiting Lutherville, Maryland, United States, 21093 Contact: Vered Stearns, MD       Vstearn1@jhmi.edu    United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Beth Overmoyer, MD, FACP    617-632-4056    bovermoyer@partners.org    Principal Investigator: Beth Overmoyer, MD, FACP          United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Catherine Van Poznak, MD       cvanpoz@med.umich.edu    United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Tufia Haddad, MD       Haddad.Tufia@mayo.edu    United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Jeremy Force, MD       Jeremy.force@duke.edu    United States, Pennsylvania University of Pennslyvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Amy Clark, MD       Clarkamy@mail.upenn.edu    United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Naoto Ueno, MD       Nueno@mdanderson.org Less <<
NCT00952289 - Completed - -
NCT00509899 Myelofibrosis ... More >> Polycythemia Vera Thrombocytosis Less << Phase 1 Phase 2 Completed - United States, Minnesota ... More >> Rochester, Minnesota, United States United States, Texas Houston, Texas, United States Less <<
NCT03610971 Chronic Phase Chronic Myeloid ... More >>Leukemia Chronic Myeloid Leukemia, Chronic Phase Less << Phase 2 Not yet recruiting January 2022 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa, Florida, United States, 33612 Contact: Anthony McLaughlin    813-745-5941    anthony.mclaughlin@moffitt.org    Contact: Kendra Sweet, M.D.    813-745-8986    kendra.sweet@moffitt.org    Principal Investigator: Kendra Sweet, M.D. Less <<
NCT03491215 Acute Graft Versus Host Diseas... More >>e Less << Phase 1 Phase 2 Recruiting July 1, 2022 Australia, Queensland ... More >> Novartis Investigative Site Recruiting Brisbane, Queensland, Australia, 4101 Australia, Victoria Novartis Investigative Site Recruiting Parkville, Victoria, Australia, 3052 Belgium Novartis Investigative Site Recruiting Bruxelles, Belgium, 1200 Novartis Investigative Site Recruiting Leuven, Belgium, 3000 Italy Novartis Investigative Site Recruiting Genova, GE, Italy, 16147 Slovenia Novartis Investigative Site Recruiting Ljubljana, Slovenia, 1000 Spain Novartis Investigative Site Recruiting Barcelona, Cataluña, Spain, 08025 Novartis Investigative Site Recruiting Madrid, Spain, 28009 Less <<
NCT03012230 Breast Carcinoma Metastatic in... More >> the Bone Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer Triple-Negative Breast Carcinoma Less << Phase 1 Recruiting March 15, 2020 United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Referral Office    855-776-0015       Principal Investigator: Donald W. Northfelt Less <<
NCT01787487 Myelodysplastic/Myeloprolifera... More >>tive Neoplasm, Unclassifiable Myelofibrosis Transformation in Essential Thrombocythemia Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Primary Myelofibrosis Less << Phase 2 Recruiting March 30, 2020 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Naval Daver    713-794-4392       Principal Investigator: Naval Daver Less <<
NCT01732445 Anemia Primar... More >>y Myelofibrosis Secondary Myelofibrosis Less << Phase 2 Completed - United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, New York Tisch Cancer Center New York, New York, United States, 10029 Less <<
NCT02528877 Acute Myeloid Leukemia in Remi... More >>ssion Primary Myelofibrosis Primary Myelofibrosis, Prefibrotic Stage Secondary Acute Myeloid Leukemia Secondary Myelofibrosis Less << Phase 1 Withdrawn(The study design was... More >> revised so a new protocol will be opened.) Less << - United States, California ... More >> City of Hope Medical Center Duarte, California, United States, 91010 Less <<
NCT00509899 - Completed - -
NCT01732445 - Completed - -
NCT03613428 Acute T Cell Leukemia Phase 1 Phase 2 Not yet recruiting March 30, 2021 -
NCT03571321 Acute Lymphoblastic Leukemia ... More >> ALL, Childhood ALL Less << Phase 1 Not yet recruiting September 5, 2024 United States, Illinois ... More >> University of Chicago Medical Center Not yet recruiting Chicago, Illinois, United States, 60637 Contact: Howie Weiner    773-702-2084    hweiner@medicine.bsd.uchicago.edu    Contact: Peggy Green, RN    (773) 702-0267    mgreen@medicine.bsd.uchicago.edu    Principal Investigator: Emily Currant, MD Less <<
NCT02155465 Lung Cancer Phase 1 Phase 2 Completed - United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering West Harrison Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center at Phelps Sleepy Hollow, New York, United States, 10591 Less <<
NCT00639002 Multiple Myeloma Phase 2 Completed - United States, California ... More >> Highland, California, United States, 92346 United States, Florida Boynton Beach, Florida, United States, 33435 United States, New York New York, New York, United States, 10011 Less <<
NCT01562873 Breast Cancer Phase 2 Terminated(Not enough response... More >>s to continue treatment.) Less << - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT00639002 - Completed - -
NCT03099304 Vitiligo Phase 2 Recruiting July 2020 -
NCT01693601 Myelofibrosis Phase 1 Phase 2 Active, not recruiting February 2019 United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT03222609 Myelofibrosis (MF) Phase 2 Recruiting June 11, 2021 United States, Alabama ... More >> UAB Comprehensive Cancer Cente /ID# 165464 Recruiting Birmingham, Alabama, United States, 35217 United States, California Ucsd /Id# 164084 Recruiting La Jolla, California, United States, 92037 Usc /Id# 164095 Recruiting Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic /ID# 164201 Recruiting Jacksonville, Florida, United States, 32224 Moffitt Cancer Center /ID# 164082 Recruiting Tampa, Florida, United States, 33612 United States, Illinois University of Chicago /ID# 164115 Recruiting Chicago, Illinois, United States, 60637 United States, Indiana Indiana Blood & Marrow Transpl /ID# 165075 Recruiting Indianapolis, Indiana, United States, 46237 United States, Massachusetts Dana-Farber Cancer Institute /ID# 162675 Recruiting Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital /ID# 162682 Recruiting Detroit, Michigan, United States, 48202 United States, New York Weill Cornell Medical College /ID# 162679 Recruiting New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center /ID# 162683 Recruiting Houston, Texas, United States, 77030 UT Health Cancer Center /ID# 164094 Recruiting San Antonio, Texas, United States, 78229 United States, Utah University of Utah /ID# 164116 Recruiting Salt Lake City, Utah, United States, 84112-5500 United Kingdom Guy's and St Thomas' NHS Found /ID# 164110 Recruiting London, London, City Of, United Kingdom, SE1 9RT Christie NHS Foundation Trust /ID# 164111 Recruiting Manchester, United Kingdom, M20 4BX Less <<
NCT01251965 Leukemia Phase 1 Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01702064 Chronic Phase Chronic Myeloid ... More >>Leukemia Less << Phase 1 Active, not recruiting March 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT03674047 Other Cancer Phase 2 Not yet recruiting March 31, 2023 United States, Massachusetts ... More >> Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Zachariah DeFilipp, MD    617-724-4000    zdefilipp@mgh.harvard.edu    Principal Investigator: Zachariah DeFilipp, MD Less <<
NCT01445769 Primary Myelofibrosis ... More >> Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Less << Phase 2 Completed - United States, California ... More >> Highland, California, United States La Jolla, California, United States Los Angeles, California, United States United States, Florida Jacksonville, Florida, United States Orange City, Florida, United States Winter Park, Florida, United States United States, Georgia Atlanta, Georgia, United States Augusta, Georgia, United States United States, Iowa Iowa City, Iowa, United States United States, Maryland Baltimore, Maryland, United States United States, Michigan Ann Arbor, Michigan, United States Southfield, Michigan, United States United States, New Jersey Morristown, New Jersey, United States United States, New York Armonk, New York, United States United States, North Carolina Hickory, North Carolina, United States United States, Ohio Canton, Ohio, United States United States, Pennsylvania Hazelton, Pennsylvania, United States Hershey, Pennsylvania, United States United States, South Carolina Charleston, South Carolina, United States United States, South Dakota Sioux Falls, South Dakota, United States United States, Texas San Antonio, Texas, United States Less <<
NCT01445769 - Completed - -
NCT00726232 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 2 Completed - United States, Texas ... More >> Houston, Texas, United States, 77030 Italy Bergamo, Italy Firenze, Italy Pavia, Italy Less <<
NCT01562873 - Terminated(Not enough response... More >>s to continue treatment.) Less << - -
NCT00726232 - Completed - -
NCT03110822 Multiple Myeloma Phase 1 Recruiting May 2020 United States, California ... More >> Comprehensive Blood and Cancer Center Recruiting Bakersfield, California, United States, 93309-0633 Contact: Nicole Henry    661-862-8548    nhenry@cbccusa.com    Principal Investigator: Ravindranath Patel, MD          California Cancer Associates for Research & Excellence (cCARE) Recruiting Encinitas, California, United States, 92024 Contact: Daniela Slavin, PhD    760-452-3909    dslavin@ccare.com    Principal Investigator: Alberto Bessudo, MD          Robert A. Moss, M.D., F.A.C.P., Inc. Recruiting Fountain Valley, California, United States, 92708 Contact: Helen Tam    714-641-1128    helen.tam@sbcglobal.net    Principal Investigator: Robert A Moss, MD          Pacific Cancer Care Recruiting Monterey, California, United States, 93940 Contact: Dorothy Tenney    831-375-4105    dtenney@pacificcancercare.com    Principal Investigator: Laura Stampleman, MD          Sansum Clinic- Ridley-Tree Cancer Center Recruiting Santa Barbara, California, United States, 93105 Contact: Heidi Heitkamp, PhD    805-879-5091    hheitkam@ridleytreecc.org    Principal Investigator: Daniel R Greenwald, MD          James R. Berenson M.D. Inc. Recruiting West Hollywood, California, United States, 90069 Contact: Regina Swift, R.N    310-623-1227    rswift@berensononcology.com    Principal Investigator: James R Berenson, MD          United States, Florida Millennium Oncology Research Clinic Recruiting Pembroke Pines, Florida, United States, 33024 Contact: Maria Contreras, MD    954-266-7885    mcontreras@millenniumoncologyfl.com    Principal Investigator: Isaac Levy, MD          United States, Maryland Regional Cancer Care Associates (RCCA) MD, LLC Recruiting Bethesda, Maryland, United States, 20817 Contact: Natalie Bongiorno, RN    301-571-2016    nbongiorno@regionalcancercare.org    Principal Investigator: Ralph Boccia, MD Less <<
NCT02015208 Chronic Lymphocytic Leukemia Phase 1 Phase 2 Completed - Canada, Ontario ... More >> Sunnybrook Odette Cancer Center Toronto, Ontario, Canada, M4N3M5 Less <<
NCT02973711 Leukemia, Chronic Myeloid Phase 1 Phase 2 Recruiting April 2021 United States, Michigan ... More >> The University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Patrick Burke, M.D.    734-647-8921    pwburke@umich.edu    Principal Investigator: Patrick Burke, M.D.          United States, North Carolina Wake Forest University Health Sciences Not yet recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Rupali Bhave, M.D.    336-713-0864    rbhave@wakehealth.edu    Contact: Megan Brown-Farmer    336-713-6913    mebrown@wakehealth.edu Less <<
NCT02613598 Hodgkin's Lymphoma ... More >> Lymphoma, Non-Hodgkin Less << Phase 1 Recruiting October 2021 United States, Michigan ... More >> University of Michgan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48187 Contact: Tycel Phillips, M.D.    734-232-2883    tycelp@umich.edu    Principal Investigator: Tycel Phillips, M.D. Less <<
NCT02066532 Metastatic Breast Cancer ... More >> Breast Carcinoma HER-2 Positive Breast Cancer Less << Phase 1 Phase 2 Recruiting December 2018 United States, New York ... More >> Mount Sinai Medical Center Recruiting New York, New York, United States, 10029 Contact: Amy Tiersten, MD    212-241-2299    amy.tiersten@mssm.edu    Principal Investigator: Amy Tiersten, MD          Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD, MS    212-305-1945    KK2693@cumc.columbia.edu    Contact: Dan Otap, CCRP    212-342-3970    DO2267@cumc.columbia.edu    Principal Investigator: Kevin Kalinsky, MD, MS          New York Hospital-Weill Cornell Medical Center Recruiting New York, New York, United States, 10065 Contact: Tessa Cigler, MD    212-821-0644    elc2007@med.cornell.edu    Principal Investigator: Tessa Cigler, MD          Montefiore Medical Center Recruiting New York, New York, United States, 10461 Contact: Della Makower, MD    718-405-8529    dmakower@montefiore.org    Principal Investigator: Della Makower, MD Less <<
NCT03654768 Chronic Phase Chronic Myelogen... More >>ous Leukemia, BCR-ABL1 Positive Less << Phase 2 Recruiting January 1, 2026 United States, Oregon ... More >> SWOG Recruiting Portland, Oregon, United States, 97239 Contact: Kendra L. Sweet    813-745-6841    kendra.sweet@moffitt.org    Principal Investigator: Kendra L. Sweet Less <<
NCT02469974 Myelofibrosis ... More >> MF Less << Not Applicable Withdrawn(no enrollments) - -
NCT03153982 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Phase 2 Not yet recruiting September 29, 2020 United States, Arizona ... More >> University of Arizona Cancer Center Not yet recruiting Tucson, Arizona, United States, 85724 Contact: Clinical Trials Office    866-278-1554    UACC-C3@uacc.arizona.edu    Sub-Investigator: Julie Bauman, MD          United States, California UCSF Helen Diller Family Comprehensive Cancer Center Not yet recruiting San Francisco, California, United States, 94131 Contact: Kyusun Cha, CCRC    415-502-3081    Kyusun.Cha@ucsf.edu Less <<
NCT02267278 Myeloproliferative Diseases Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00638378 Prostate Cancer Phase 2 Terminated(According to the pr... More >>otocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.) Less << - United States, California ... More >> Highland, California, United States Montebello, California, United States Mountain View, California, United States United States, Illinois Galesburg, Illinois, United States United States, Kansas Overland Park, Kansas, United States Wichita, Kansas, United States United States, Michigan Grand Rapids, Michigan, United States United States, Missouri Jefferson City, Missouri, United States United States, Montana Great Falls, Montana, United States, 59405 United States, New Jersey Cherry Hill, New Jersey, United States United States, New York Staten Island, New York, United States United States, North Dakota Bismarck, North Dakota, United States United States, Pennsylvania Bethlehem, Pennsylvania, United States United States, South Carolina Sumter, South Carolina, United States United States, Washington Lacey, Washington, United States Less <<
NCT01950780 Alopecia Areata Phase 2 Completed - United States, New York ... More >> Columbia University Medical Center, Department of Dermatology New York, New York, United States, 10032 Less <<
NCT00638378 - Terminated(According to the pr... More >>otocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.) Less << - -
NCT02723994 Leukemia Phase 2 Recruiting May 2024 -
NCT01340651 Myelofibrosis Phase 2 Completed - United States, Arizona ... More >> Scottsdale, Arizona, United States United States, Florida Winter Park, Florida, United States United States, Texas Houston, Texas, United States, TX Less <<
NCT03745651 Atopic Dermatitis Phase 3 Recruiting September 2020 United States, Florida ... More >> San Marcus Research Clinic Inc Recruiting Miami, Florida, United States, 33015 Well Pharma Medical Research Corporation Not yet recruiting Miami, Florida, United States, 33143 Forward Clinical Trials Inc Not yet recruiting Tampa, Florida, United States, 33624 United States, Georgia Clinical Research Atlanta Not yet recruiting Stockbridge, Georgia, United States, 30281 United States, Kentucky Derm Research LLC Not yet recruiting Louisville, Kentucky, United States, 40217 Dermatology Specialists PSC Not yet recruiting Louisville, Kentucky, United States, 40241 United States, New Hampshire ActivMed Practices & Research Inc Not yet recruiting Portsmouth, New Hampshire, United States, 03801 United States, New Jersey Hassman Research Institute Not yet recruiting Berlin, New Jersey, United States, 08009 United States, Ohio Synexus Clinical Research US, Inc. - Cincinnati Not yet recruiting Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Paddington Testing Company Inc Not yet recruiting Philadelphia, Pennsylvania, United States, 19103 United States, South Carolina Synexus Clinical Research US, Inc. - Anderson Not yet recruiting Anderson, South Carolina, United States, 29621 United States, Texas Clinical Trials of Texas Incorporated Not yet recruiting San Antonio, Texas, United States, 78229 Center for Clinical Studies Not yet recruiting Webster, Texas, United States, 77598 United States, Virginia Clinical Research Partners LLC Not yet recruiting Henrico, Virginia, United States, 23233 United States, Washington Dermatology Specialists of Spokane Not yet recruiting Spokane, Washington, United States, 99204 Less <<
NCT03745638 Atopic Dermatitis Phase 3 Recruiting September 2020 -
NCT02092324 Atypical Chronic Myeloid Leuke... More >>mia, BCR-ABL1 Negative Chronic Neutrophilic Leukemia Less << Phase 2 Recruiting - United States, California ... More >> Stanford Cancer Institute Palo Alto Recruiting Palo Alto, California, United States, 94304 Contact: Jason Gotlib    650-736-1253    gotlib@stanford.org    Principal Investigator: Jason Gotlib          United States, Georgia Emory University Hospital/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Elliott F. Winton    404-778-4755    ewinton@emory.edu    Principal Investigator: Elliott F. Winton          United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh    314-362-8846    stoh@dom.wustl.edu    Principal Investigator: Stephen Oh          United States, Oregon OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Kim-Hien Dao    503-494-7894    daok@ohsu.edu    Principal Investigator: Kim-Hien Dao          United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Recruiting Dallas, Texas, United States, 75390 Contact: Robert H. Collins    214-648-4155    robert.collins@utsouthwestern.edu    Principal Investigator: Robert H. Collins          M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jorge E. Cortes    713-794-5783    jcortes@mdanderson.org    Principal Investigator: Jorge E. Cortes          United States, Utah Huntsman Cancer Institute/University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Contact: Michael W. Deininger    801-213-5684    michael.deininger@hci.utah.edu    Principal Investigator: Michael W. Deininger Less <<
NCT03112603 Graft-versus-host Disease (GVH... More >>D) Less << Phase 3 Recruiting January 2022 -
NCT03147742 - - - United States, Florida ... More >> Blood & Marrow Transplant Center Orlando, Florida, United States, 32804 Principal Investigator: Dr. Steven Goldstein          United States, Kansas Cancer Center of Kansas Wichita, Kansas, United States, 67214 Principal Investigator: Dr. Shaker Dakhil          United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02215 Principal Investigator: Dr. Yin-Bin Chen          United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109-5271 Principal Investigator: Dr. Sarah Anand          United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Principal Investigator: Dr. Alfred Gillio          United States, New York Weill Cornell Medical College New York, New York, United States, 10021 Principal Investigator: Dr. Tsiporah Shore          Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Principal Investigator: Dr. Miguel-Angel Perales          United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 Principal Investigator: Dr. Rachel Cook          United States, Pennsylvania Gettysburg Cancer Center Gettysburg, Pennsylvania, United States, 17325 Principal Investigator: Dr. Satish Shah          Allegheny Health Network Cancer Institute Pittsburgh, Pennsylvania, United States, 15224 Principal Investigator: Dr. Anna Koget          United States, South Carolina Greenville Health System Cancer Institute Greenville, South Carolina, United States, 29615 Principal Investigator: Dr. Suzanne Fanning          United States, South Dakota Avera Research Institute Sioux Falls, South Dakota, United States, 57105 Principal Investigator: Dr. Vinod Parameswaran          United States, Texas Medical City Dallas Hospital Dallas, Texas, United States, 75230 Principal Investigator: Dr. Vikas Bhushan          United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 Principal Investigator: Dr. Paul Carpenter          United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Principal Investigator: Dr. Parameswaran Hari Less <<
NCT03681561 Hodgkin Lymphoma Phase 1 Phase 2 Recruiting March 2024 United States, Minnesota ... More >> University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Erin Zielinski    612-624-0937    eezielin@umn.edu    Principal Investigator: Veronika Bachanova, MD Less <<
NCT02953678 Graft-versus-host Disease (GVH... More >>D) Less << Phase 2 Active, not recruiting June 2020 -
NCT01340651 - Completed - -
NCT02917096 Primary Myelofibrosis ... More >> Secondary Myelofibrosis Less << Not Applicable Recruiting October 2019 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Haris Ali    626-256-4673       Principal Investigator: Haris Ali Less <<
NCT02041429 Recurrent Breast Cancer ... More >> Metastatic Breast Cancer Less << Phase 1 Phase 2 Active, not recruiting January 2021 United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT03286530 Acute Myeloid Leukemia ... More >> Acute Myeloid Leukemia in Remission Allogeneic Stem Cell Transplantation Less << Phase 2 Recruiting September 1, 2024 United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02115 Contact: Myrna Nahas, MD    617-667-9920       Principal Investigator: Myrna Nahas, MD          Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Gabriella Hobbs, MD    617-726-8748       Principal Investigator: Gabriella Hobbs, MD          United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63130 Contact: Mark Schroeder, MD       markschroeder@wustl.edu    Principal Investigator: Mark Schroeder, MD          United States, Ohio The Ohio State University Recruiting Columbus, Ohio, United States, 43210 Contact: Sumithira Vasu, MBBS       Sumithira.Vasu@osumc.edu    Principal Investigator: Sumithira Vasu, MBBS          United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37235 Contact: Michael Byrne, MD       Michael.Byrne@vanderbilt.edu    Principal Investigator: Michael Byrne, MD Less <<
NCT03514069 Glioma Gliobl... More >>astoma Less << Phase 1 Recruiting December 2020 United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Manmeet Ahluwalia, MD    866-223-8100    CancerCenterResearch@ccf.org    Principal Investigator: Manmeet Ahluwalia, MD Less <<
NCT03257644 Atopic Dermatitis Phase 1 Suspended(Study is currently o... More >>n hold pending amendment update.) Less << December 2019 United States, California ... More >> Children's Hospital of Los Angeles Los Angeles, California, United States, 90027 Rady Children's Hospital - San Diego San Diego, California, United States, 92123 United States, Colorado National Jewish Health Denver, Colorado, United States, 80206 United States, Illinois Northwestern University Department of Dermatology Chicago, Illinois, United States, 60611 United States, Michigan David Fivenson, MD, Dermatology, PLC Ann Arbor, Michigan, United States, 48103 United States, North Carolina Wake Research Associates Raleigh, North Carolina, United States, 27612 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 United States, Texas Texas Dermatology and Laser Specialist Clinical Research San Antonio, Texas, United States, 78218 Less <<
NCT03123588 MPN (Myeloproliferative Neopla... More >>sms) Less << Phase 2 Recruiting June 2020 -
NCT03722407 Chronic Myelomonocytic Leukemi... More >>a Leukemia Less << Phase 2 Not yet recruiting February 1, 2024 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa, Florida, United States, 33612 Contact: Anthony McLaughlin    813-745-5941    Anthony.McLaughlin@moffitt.org    Principal Investigator: Eric Padron, MD          Sub-Investigator: Rami Komrokji, MD          Sub-Investigator: Alan F List, MD          Sub-Investigator: Jeffrey E Lancet, MD          Sub-Investigator: Kendra Sweet, MD          Sub-Investigator: Bijal Shah, MD          Sub-Investigator: David Sallman, MD          Sub-Investigator: Chetasi Talati, MD          Sub-Investigator: Andrew Kuykendall, MD          Sub-Investigator: Maria Balasis, BS          Sub-Investigator: Brooke Fridley, PhD Less <<
NCT02593929 Head and Neck Squamous Cell Ca... More >>rcinoma Less << Early Phase 1 Withdrawn - -
NCT01790295 Primary Myelofibrosis ... More >> Post Polycythemia Vera Myelofibrosis Post Essential Thrombocythemia Myelofibrosis Less << Phase 2 Active, not recruiting February 2021 United States, Georgia ... More >> Emory Hospital Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University, Robert h. Lurie Comprehensive Cancer Center Chicago, Illinois, United States, 60611 United States, Kansas University of Kansas Cancer Center Westwood, Kansas, United States, 66205 United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, North Carolina Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States, 27103 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Canada Princess Margaret Cancer Centre, University of Toronto Toronto, Canada, M5G 2M9 United Kingdom University of Oxford Oxford, United Kingdom, OX3 9DS Less <<
NCT02257138 Blasts More Than 20 Percent of... More >> Bone Marrow Nucleated Cells Blasts More Than 20 Percent of Peripheral Blood White Cells Myelodysplastic/Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Less << Phase 1 Phase 2 Recruiting February 1, 2019 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Farhad Ravandi-Kashani    713-745-0394       Principal Investigator: Farhad Ravandi-Kashani Less <<
NCT02809976 Vitiligo Phase 2 Completed - United States, Massachusetts ... More >> Tufts Medical Center Boston, Massachusetts, United States, 02111 Less <<
NCT01895842 Leukemia Phase 1 Active, not recruiting February 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03041636 Malignant Neoplasms Stated as ... More >>Primary Lymphoid Haematopoietic Other Diseases of Blood and Blood-Forming Organs Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Less << Phase 2 Recruiting March 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       zestrov@mdanderson.org Less <<
NCT02784496 Myelofibrosis Phase 2 Active, not recruiting September 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01431209 Recurrent Diffuse Large B-Cell... More >> Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Less << Phase 2 Active, not recruiting December 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less <<
NCT02131584 Chronic Lymphocytic Leukemia ... More >> Fatigue Less << Phase 2 Active, not recruiting September 30, 2022 United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02928978 Ductal Carcinoma In Situ ... More >> Atypical Lobular Hyperplasia Atypical Ductal Hyperplasia Lobular Carcinoma In Situ Less << Phase 2 Recruiting January 2020 United States, Texas ... More >> Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Kristen Otte    713-798-8874    clinical-research@breastcenter.tmc.edu    Principal Investigator: Julie Nangia, M.D.          Sub-Investigator: Mothaffar Rimawi, M.D.          Sub-Investigator: Matthew Ellis, M.D.          Sub-Investigator: Maryam Nemati Shaefee, M.D.          Sub-Investigator: C. Kent Osborne, M.D.          Sub-Investigator: Angela Coscio, M.D. Less <<
NCT02493530 Myelofibrosis ... More >> Polycythemia Vera Less << Phase 1 Recruiting December 2019 United States, Arizona ... More >> Mayo Clinic - Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Clinical Trials Office    855-776-0015       Principal Investigator: Ruben Mesa, MD          United States, Colorado University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Clinical Trials Office    720-848-0018       Principal Investigator: Daniel A Pollyea, MD, MS          United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Clinical Trials Office    800-811-8480       Principal Investigator: Michael R Savona, MD          United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Clinical Trials Office    414-805-1118       Principal Investigator: Laura C. Michaelis, MD Less <<
NCT02912754 Leukemia, Lymphocytic, Chronic... More >>, B-Cell Less << Phase 1 Phase 2 Not yet recruiting August 2019 Canada, Ontario ... More >> Sunnybrook Odette Cancer Center Not yet recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Geetha Geetha Yogendran, BSc    416-480-5000 ext 89565    geetha.yogendran@sunnybrook.ca    Contact: Lindsay McCaw, MSc    416-480-6100 ext 4244    lindsay.mccaw@sunnybrook.ca    Principal Investigator: david e spaner, MD          Sunnybrook Odette Cancer Center Toronto, Ontario, Canada, M4N3M5 Less <<
NCT03427866 Myelofibrosis Phase 2 Recruiting September 30, 2021 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02214 Contact: Meridith E. Bailey, MD    617-643-4970    mebailey@partners.org    Principal Investigator: Gabriela Hobbs, MD          United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37235 Contact: Michael Byrne, DO       Michael.Byrne@vanderbilt.edu    Principal Investigator: Michael Byrne, DO Less <<
NCT03774082 Graft vs Host Disease PHASE2 COMPLETED 2024-08-26 Novartis Investigative Site, S... More >>ao Paulo, 04039 001, Brazil|Novartis Investigative Site, Toronto, Ontario, M5G 1X8, Canada|Novartis Investigative Site, Praha 5, 150 06, Czechia|Novartis Investigative Site, Tamil Nadu, Chennai, 600035, India|Novartis Investigative Site, Pune, Maharashtra, 411004, India|Novartis Investigative Site, Bangalore, 560099, India|Novartis Investigative Site, Delhi, 110 085, India|Novartis Investigative Site, Roma, RM, 00165, Italy|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Saitama, 330 8777, Japan|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 05505, Korea, Republic of|Novartis Investigative Site, Saint Petersburg, 197022, Russian Federation|Novartis Investigative Site, Bratislava, 833 40, Slovakia|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Zuerich, CH - 8032, Switzerland|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Adana, 1330, Turkey|Novartis Investigative Site, Antalya, 07000, Turkey|Novartis Investigative Site, Antalya, 07070, Turkey Less <<
NCT01493414 Myelofibrosis PHASE3 COMPLETED 2017-01-26 Novartis Investigative Site, A... More >>lger, Algeria|Novartis Investigative Site, Caba, Buenos Aires, 1209, Argentina|Novartis Investigative Site, Caba, Buenos Aires, C1221ADC, Argentina|Novartis Investigative Site, Paraná, Entre Rios, E3100BBJ, Argentina|Novartis Investigative Site, Buenos Aires, C1114AAN, Argentina|Novartis Investigative Site, Cordoba, X5016KEH, Argentina|Novartis Investigative Site, Corrientes, W3410AVV, Argentina|Novartis Investigative Site, Innsbruck, Tyrol, 6020, Austria|Novartis Investigative Site, Graz, A-8036, Austria|Novartis Investigative Site, Linz, 4010, Austria|Novartis Investigative Site, Linz, A-4010, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Wien, 1140, Austria|Novartis Investigative Site, Wien, A-1090, Austria|Novartis Investigative Site, Arlon, Luxembourg, 1210, Belgium|Novartis Investigative Site, Antwerpen, 2060, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Brussel, 1090, Belgium|Novartis Investigative Site, Bruxelles, 1070, Belgium|Novartis Investigative Site, Charleroi, 6000, Belgium|Novartis Investigative Site, Edegem, 2650, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Hasselt, 3500, Belgium|Novartis Investigative Site, Kortrijk, 8500, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Roeselare, 8800, Belgium|Novartis Investigative Site, Wilrijk, 2610, Belgium|Novartis Investigative Site, Yvoir, 5530, Belgium|Novartis Investigative Site, Goiania, GO, 74605-050, Brazil|Novartis Investigative Site, Belo Horizonte, MG, 30130-100, Brazil|Novartis Investigative Site, Curitiba, PR, 80060-900, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, 20.211-030, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90035-003, Brazil|Novartis Investigative Site, Campinas, SP, 13083-970, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, 14048-900, Brazil|Novartis Investigative Site, S?o Paulo, SP, 01224-000, Brazil|Novartis Investigative Site, S?o Paulo, SP, 05651-901, Brazil|Novartis Investigative Site, S?o Paulo, SP, 08270-070, Brazil|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, Vancouver, British Columbia, V6Z1Y6, Canada|Novartis Investigative Site, Moncton, New Brunswick, E1C 6Z8, Canada|Novartis Investigative Site, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 1V7, Canada|Novartis Investigative Site, Hamilton, Ontario, L8V 5C2, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Windsor, Ontario, N8W 2X3, Canada|Novartis Investigative Site, Montreal, Quebec, H2W 1S6, Canada|Novartis Investigative Site, Québec, Quebec, G1J 1Z4, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Novartis Investigative Site, Bogota, Cundinamarca, 111411, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Brno, Czech Republic, 639 00, Czechia|Novartis Investigative Site, Hradec Kralove, Czech Republic, 500 05, Czechia|Novartis Investigative Site, Praha 2, Czech Republic, 128 20, Czechia|Novartis Investigative Site, Olomouc, 775 20, Czechia|Novartis Investigative Site, Mannheim, Baden-Württemberg, 68305, Germany|Novartis Investigative Site, Aachen, 52074, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Bamberg, 96049, Germany|Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Berlin, 14195, Germany|Novartis Investigative Site, Bochum, 44787, Germany|Novartis Investigative Site, Bonn, 53113, Germany|Novartis Investigative Site, Bonn, 53119, Germany|Novartis Investigative Site, Bottrop, 46236, Germany|Novartis Investigative Site, Bremen, 28177, Germany|Novartis Investigative Site, Chemnitz, 09113, Germany|Novartis Investigative Site, Darmstadt, 64283, Germany|Novartis Investigative Site, Dortmund, 44263, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Duisburg, 47166, Germany|Novartis Investigative Site, Düsseldorf, 40225, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Frankfurt, Oder, 15236, Germany|Novartis Investigative Site, Frankfurt, 60389, Germany|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Friedrichshafen, 88045, Germany|Novartis Investigative Site, Goslar, 38642, Germany|Novartis Investigative Site, Greifswald, 17475, Germany|Novartis Investigative Site, G?ttingen, D-37075, Germany|Novartis Investigative Site, Halle, 06110, Germany|Novartis Investigative Site, Hamburg, 20099, Germany|Novartis Investigative Site, Hamburg, 20246, Germany|Novartis Investigative Site, Hamm, 59063, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Hildesheim, 31135, Germany|Novartis Investigative Site, Ingolstadt, 85049, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Kiel, D-24116, Germany|Novartis Investigative Site, Koeln, 50671, Germany|Novartis Investigative Site, K?ln, 50937, Germany|Novartis Investigative Site, Leer, 26789, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, Marburg, 35037, Germany|Novartis Investigative Site, Marburg, 35039, Germany|Novartis Investigative Site, Minden, 32429, Germany|Novartis Investigative Site, Moers, 47441, Germany|Novartis Investigative Site, Muenchen, 80331, Germany|Novartis Investigative Site, Muenchen, 81241, Germany|Novartis Investigative Site, München, 81675, Germany|Novartis Investigative Site, Nuernberg, 90403, Germany|Novartis Investigative Site, Oldenburg, 26133, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Stuttgart, 70376, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Athens, GR, 115 27, Greece|Novartis Investigative Site, Athens, GR, GR-106 76, Greece|Novartis Investigative Site, Athens, GR 11527, Greece|Novartis Investigative Site, Patras, 265 00, Greece|Novartis Investigative Site, Budapest, H-1097, Hungary|Novartis Investigative Site, Debrecen, H-4032, Hungary|Novartis Investigative Site, Kaposvár, 7400, Hungary|Novartis Investigative Site, Szeged, H-6720, Hungary|Novartis Investigative Site, Szombathely, 9700, Hungary|Novartis Investigative Site, Cork City, Cork, Ireland|Novartis Investigative Site, Afula, 1834111, Israel|Novartis Investigative Site, Haifa, 3339419, Israel|Novartis Investigative Site, Jerusalem, 9112001, Israel|Novartis Investigative Site, Petach Tikva, 49100, Israel|Novartis Investigative Site, Ramat Gan, 5266202, Israel|Novartis Investigative Site, Tel-Aviv, 6423906, Israel|Novartis Investigative Site, Alessandria, AL, 15100, Italy|Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, Avellino, AV, 83100, Italy|Novartis Investigative Site, Bari, BA, 70124, Italy|Novartis Investigative Site, Bergamo, BG, 24128, Italy|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Brescia, BS, 25123, Italy|Novartis Investigative Site, Cagliari, CA, 09100, Italy|Novartis Investigative Site, Cagliari, CA, 09126, Italy|Novartis Investigative Site, Catania, CT, 95100, Italy|Novartis Investigative Site, Catania, CT, 95124, Italy|Novartis Investigative Site, Catanzaro, CZ, 88100, Italy|Novartis Investigative Site, Cona, FE, 44100, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, 71013, Italy|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Lecce, LE, 73100, Italy|Novartis Investigative Site, Monza, MB, 20900, Italy|Novartis Investigative Site, Milano, MI, 20122, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Milano, MI, 20162, Italy|Novartis Investigative Site, Modena, MO, 41100, Italy|Novartis Investigative Site, Palermo, PA, 90146, Italy|Novartis Investigative Site, Padova, PD, 35128, Italy|Novartis Investigative Site, Pescara, PE, 65124, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Pesaro, PU, 61100, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Rionero in Vulture, PZ, 85028, Italy|Novartis Investigative Site, Ravenna, RA, 48100, Italy|Novartis Investigative Site, Reggio Calabria, RC, 89124, Italy|Novartis Investigative Site, Reggio Emilia, RE, 42123, Italy|Novartis Investigative Site, Roma, RM, 00128, Italy|Novartis Investigative Site, Roma, RM, 00133, Italy|Novartis Investigative Site, Roma, RM, 00144, Italy|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Roma, RM, 00168, Italy|Novartis Investigative Site, Roma, RM, 00185, Italy|Novartis Investigative Site, Pagani, SA, 84016, Italy|Novartis Investigative Site, Siena, SI, 53100, Italy|Novartis Investigative Site, Taranto, TA, 74100, Italy|Novartis Investigative Site, Orbassano, TO, 10043, Italy|Novartis Investigative Site, Torino, TO, 10126, Italy|Novartis Investigative Site, Terni, TR, 05100, Italy|Novartis Investigative Site, Treviso, TV, 31100, Italy|Novartis Investigative Site, Udine, UD, 33100, Italy|Novartis Investigative Site, Varese, VA, 21100, Italy|Novartis Investigative Site, Venezia, VE, 30174, Italy|Novartis Investigative Site, Vicenza, VI, 36100, Italy|Novartis Investigative Site, Verona, VR, 37126, Italy|Novartis Investigative Site, Ronciglione, VT, 01100, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Napoli, 80132, Italy|Novartis Investigative Site, Napoli, 80136, Italy|Novartis Investigative Site, Novara, 28100, Italy|Novartis Investigative Site, Pavia, 27100, Italy|Novartis Investigative Site, Perugia, 06129, Italy|Novartis Investigative Site, Mexico, Distrito Federal, 06726, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, 44280, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, 64020, Mexico|Novartis Investigative Site, Hermosillo, Sonora, 83000, Mexico|Novartis Investigative Site, Puebla, 72000, Mexico|Novartis Investigative Site, Marrakech, Morocco|Novartis Investigative Site, Gdansk, 80-958, Poland|Novartis Investigative Site, Katowice, 40-027, Poland|Novartis Investigative Site, Krakow, 31-503, Poland|Novartis Investigative Site, Opole, 45-372, Poland|Novartis Investigative Site, Torun, 87-100, Poland|Novartis Investigative Site, Warszawa, 02-776, Poland|Novartis Investigative Site, Coimbra, 3000-075, Portugal|Novartis Investigative Site, Faro, 8000-386, Portugal|Novartis Investigative Site, Lisboa, 1749-035, Portugal|Novartis Investigative Site, Porto, 4099-001, Portugal|Novartis Investigative Site, Vila Real, 5000 - 508, Portugal|Novartis Investigative Site, Irkutsk, 664079, Russian Federation|Novartis Investigative Site, Moscow, 125167, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, 603126, Russian Federation|Novartis Investigative Site, Novosibirsk, 630051, Russian Federation|Novartis Investigative Site, Rostov-on-Don, 344022, Russian Federation|Novartis Investigative Site, St Petersburg, 191024, Russian Federation|Novartis Investigative Site, St Petersburg, 197341, Russian Federation|Novartis Investigative Site, Jeddah, 21423, Saudi Arabia|Novartis Investigative Site, Riyadh, 11426, Saudi Arabia|Novartis Investigative Site, Bratislava, 85107, Slovakia|Novartis Investigative Site, Soweto, Gauteng, 2013, South Africa|Novartis Investigative Site, Cape Town, Western Province, 7801, South Africa|Novartis Investigative Site, Johannesburg, 2196, South Africa|Novartis Investigative Site, Pretoria, 0001, South Africa|Novartis Investigative Site, Pretoria, 0027, South Africa|Novartis Investigative Site, Ferrol, A Coruna, 15405, Spain|Novartis Investigative Site, Granada, Andalucia, 18014, Spain|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Cadiz, Andalucía, 11009, Spain|Novartis Investigative Site, Jaen, Andalucía, 23007, Spain|Novartis Investigative Site, Oviedo, Asturias, 33006, Spain|Novartis Investigative Site, Sabadell, Barcelona, 08208, Spain|Novartis Investigative Site, Santander, Cantabria, 39008, Spain|Novartis Investigative Site, Toledo, Castilla La Mancha, 45071, Spain|Novartis Investigative Site, Burgos, Castilla Y Leon, 09005, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain|Novartis Investigative Site, Valladolid, Castilla Y Leon, 47012, Spain|Novartis Investigative Site, Badalona, Catalunya, 08916, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08003, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Girona, Catalunya, 17007, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Tarragona, Catalunya, 43005, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, 03010, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46026, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, 07120, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Las Palmas De G.C, 35010, Spain|Novartis Investigative Site, Alcala de Henares, Madrid, 28805, Spain|Novartis Investigative Site, Majadahonda, Madrid, 28222, Spain|Novartis Investigative Site, Pozuelo de Alarcón, Madrid, 28223, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, 28702, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Pamplona, Navarra, 31008, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Logrono, Rioja, 26006, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, 48903, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, 35016, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Zaragoza, 50009, Spain|Novartis Investigative Site, Zaragoza, 50015, Spain|Novartis Investigative Site, Bangkok, 10330, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand|Novartis Investigative Site, Chiang Mai, 50200, Thailand|Novartis Investigative Site, Sfax, Tunisie, 3029, Tunisia|Novartis Investigative Site, Sousse, 4000, Tunisia|Novartis Investigative Site, Tunis, 1008, Tunisia|Novartis Investigative Site, Tunis, Tunisia Less <<
NCT01558739 Primary Myelofibrosis (PMF)|Po... More >>st Polycythaemia Myelofibrosis (PPV MF)|Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Less << PHASE4 COMPLETED 2025-01-14 Novartis Investigative Site, C... More >>ardiff, Wales, CF14 4XN, United Kingdom|Novartis Investigative Site, Bournemouth, BH7 7DW, United Kingdom|Novartis Investigative Site, East Yorkshire, HU16 5JQ, United Kingdom|Novartis Investigative Site, Edinburgh, EH4 2XU, United Kingdom|Novartis Investigative Site, Leicester, LE7 5WW, United Kingdom|Novartis Investigative Site, Liverpool, L7 8XP, United Kingdom|Novartis Investigative Site, London, SE1 9RT, United Kingdom|Novartis Investigative Site, London, W12 0HS, United Kingdom|Novartis Investigative Site, Manchester, M13 9NT, United Kingdom|Novartis Investigative Site, Oxford, OX3 7LJ, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.37mL

2.47mL

1.24mL

24.73mL

4.95mL

2.47mL

References

 

Historical Records

Categories